Karyopharm Therapeutics Revenue and Competitors

Boston, MA USA



Total Funding



Estimated Revenue & Valuation

  • Karyopharm Therapeutics's estimated annual revenue is currently $118.7M per year.(i)
  • Karyopharm Therapeutics received $Undisclosed in venture funding in January 2015.
  • Karyopharm Therapeutics's estimated revenue per employee is $277,220
  • Karyopharm Therapeutics's total funding is $381.7M.
  • Karyopharm Therapeutics's current valuation is $607.4M. (January 2022)

Employee Data

  • Karyopharm Therapeutics has 428 Employees.(i)
  • Karyopharm Therapeutics grew their employee count by -8% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
Add Company

Karyopharm Therapeutics Inc. is a clinical-stage pharmaceutical company focused on discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases. For more information, please visit www.karyopharm.com

keywords:Biotechnology,Cleantech,Healthcare,Marketing,Pharmaceuticals,Wind Power


Total Funding


Number of Employees


Revenue (est)


Employee Growth %





Karyopharm Therapeutics News

2022-04-20 - Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Expected to Post Quarterly Sales of $35.14 Million

Six analysts have made estimates for Karyopharm Therapeutics' earnings. The highest sales estimate is $37.23 million and the lowest is $31.33...

2022-04-17 - Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Sees Large ...

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Sees Large Increase in Short Interest. Posted by admin on Apr 19th, 2022.

2022-03-30 - Karyopharm Therapeutics Reports Inducement Grants Under ...

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company pioneering novel cancer therapies. Since its founding,...

2021-11-03 - Karyopharm Reports Strong Third Quarter 2021 Financial Results and Provides Business Highlights

NEWTON, Mass., Nov. 3, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today reported financial results for the quarter ended September 30, 2021 and provided business highlights. "Driven by acceleratio ...

2021-10-21 - Karyopharm Therapeutics : Announces Dosing of First Patient in a Phase 2 Study Investigating Oral Eltanexor in HMA Refractory Myelodysplastic Syndrome

NEWTON, Mass., Oct. 21, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced dosing of the first patient in the Phase 2 expansion of an ongoing open-label Phase 1/2 study investigating eltane ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding

Karyopharm Therapeutics Funding

DateAmountRoundLead InvestorsReference
2011-11-03$10.0MA2Chione LtdArticle
2013-05-21$48.2MBDelphi VenturesArticle
2015-01-07$UndisclosedUndisclosedBofA Merrill LynchArticle